Literature DB >> 29218834

Comparative evaluation of simple indices using a single fasting blood sample to estimate beta cell function after islet transplantation.

Justyna E Gołębiewska1,2, Julia Solomina1, Celeste Thomas3, Mark R Kijek1, Piotr J Bachul1,4, Lindsay Basto1, Karolina Gołąb1, Ling-Jia Wang1, Natalie Fillman1, Martin Tibudan1, Kamil Ciepły1, Louis Philipson3, Alicja Dębska-Ślizień2, J Michael Millis1, John Fung1, Piotr Witkowski1.   

Abstract

Six single fasting blood sample-based indices-Secretory Unit of Islet Transplant Objects (SUITO), Transplant Estimated Function (TEF), Homeostasis Model Assessment (HOMA)2-B%, C-peptide/glucose ratio (CP/G), C-peptide/glucose creatinine ratio (CP/GCr), and BETA-2 score-were compared against commonly used 90-minute mixed meal tolerance test (MMTT) serum glucose and beta score to assess which of them best recognizes the state of acceptable blood glucose control without insulin supplementation after islet allotransplantation (ITx). We also tested whether the indices could identify the success of ITx based on the Igls classification of beta cell graft function. We analyzed values from 47 MMTT tests in 4 patients with up to 140 months follow-up and from 54 MMTT tests in 13 patients with up to 42 months follow-up. SUITO, CP/G, HOMA2-B%, and BETA-2 correlated well with the 90-minute glucose of the MMTT and beta-score (r 0.54-0.76), whereas CP/GCr showed a modest performance (r 0.41-0.52) while TEF showed little correlation. BETA-2 and SUITO were the best identifiers and predictors of the need for insulin support, glucose intolerance, and ITx success (P < .001), while HOMA2-B% and TEF were unreliable. Single fasting blood sample SUITO and BETA-2 scores are very practical alternative tools that allow for frequent assessments of graft function.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; islet transplantation; islets of Langerhans, monitoring; physiologic

Mesh:

Substances:

Year:  2018        PMID: 29218834     DOI: 10.1111/ajt.14620

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  4 in total

1.  HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Authors:  Jamie L Felton; David Cuthbertson; Megan Warnock; Kuldeep Lohano; Farah Meah; John M Wentworth; Jay Sosenko; Carmella Evans-Molina
Journal:  Diabetologia       Date:  2021-10-12       Impact factor: 10.460

2.  Islet cell autotransplantation update.

Authors:  Khawla F Ali; Betul Hatipoglu
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2019-04-18

3.  Fasting parameters for estimation of stimulated β cell function in islet transplant recipients with or without basal insulin treatment.

Authors:  Bas S Uitbeijerse; Michiel F Nijhoff; Jacob K Sont; Eelco J P de Koning
Journal:  Am J Transplant       Date:  2020-07-13       Impact factor: 8.086

4.  Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

Authors:  Piotr J Bachul; Karolina Golab; Lindsay Basto; Steven Zangan; Jordan S Pyda; Angelica Perez-Gutierrez; Peter Borek; Ling-Jia Wang; Martin Tibudan; Dong-Kha Tran; Roi Anteby; Gabriela S Generette; Jędrzej Chrzanowski; Wojciech Fendler; Laurencia Perea; Kumar Jayant; Aaron Lucander; Celeste Thomas; Louis Philipson; J Michael Millis; John Fung; Piotr Witkowski
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.